Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of torudokimab in healthy subjects
NCT03343587Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2017
- Primary completion
- Nov 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of torudokimab in atopic dermatitis (AD) and asthma (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s). Started Nov 2017; status: completed.
02
Drugs
torudokimab
03
Conditions
atopic dermatitis (AD)asthma
Beyond the preview
Go deeper on NCT03343587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03343587.